Open AccessShort term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy
Author(s) -
Ronald E Cox,
Marie Parish,
Carolyn Oxencis,
Edward J. McKenna,
Bicky Thapa,
Sakti Chakrabarti
Publication year - 2022
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v13.i7.599
Subject(s) - medicine , adverse effect , common terminology criteria for adverse events , vaccination , systemic therapy , disease , cancer , immunology , breast cancer
There are currently three coronavirus disease 2019 (COVID-19) vaccines approved by the United States Food and Drug Administration to prevent coronavirus infection. However, robust data are unavailable on the adverse events of the vaccines in patients with solid tumor malignancies undergoing systemic therapies.